Bruton’s Tyrosine Kinase Inhibitors

Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase. At first, it was identified as the defective protein in human X-linked agammaglobulinemia (XLA) and is also called B-cell progenitor kinase (BPK) or agammaglobulinemia tyrosine kinase (ATK).

Bruton’s tyrosine kinase (BTK)

BTK’s Role in Humans

BTK, which is a member of the Tec family of protein tyrosine kinases, has a vital role to play in the development, differentiation, and signaling of B-lymphocytes. XLA in humans and X-linked immunodeficiency (Xid) in mice are caused by mutations in the Btk gene. When the Btk gene is activated, a cascade of signaling events is triggered, resulting in the generation of cytoskeletal rearrangements, calcium mobilization and fluxes, and transcriptional regulation involving nuclear factor of activated T cells (NFAT) and nuclear factor-kappaB (NF-kB).

Inhibition of BTK

BTK inhibition is of therapeutic importance while treating B cell chronic lymphocytic leukemia (B-CLL) and B cell-related hematological cancers (for example, non-Hodgkin lymphoma (NHL), as well as autoimmune diseases such as rheumatoid arthritis. BioVision is pleased to provide numerous small molecule BTK inhibitors for research.

BioVision Incorporated

BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.

BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 3, 2020 at 1:41 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2020, April 03). Bruton’s Tyrosine Kinase Inhibitors. News-Medical. Retrieved on September 20, 2020 from https://www.news-medical.net/whitepaper/20190801/Brutons-Tyrosine-Kinase-Inhibitors.aspx.

  • MLA

    BioVision Incorporated. "Bruton’s Tyrosine Kinase Inhibitors". News-Medical. 20 September 2020. <https://www.news-medical.net/whitepaper/20190801/Brutons-Tyrosine-Kinase-Inhibitors.aspx>.

  • Chicago

    BioVision Incorporated. "Bruton’s Tyrosine Kinase Inhibitors". News-Medical. https://www.news-medical.net/whitepaper/20190801/Brutons-Tyrosine-Kinase-Inhibitors.aspx. (accessed September 20, 2020).

  • Harvard

    BioVision Incorporated. 2020. Bruton’s Tyrosine Kinase Inhibitors. News-Medical, viewed 20 September 2020, https://www.news-medical.net/whitepaper/20190801/Brutons-Tyrosine-Kinase-Inhibitors.aspx.

Other White Papers by this Supplier